Technical analysis of REGENXBIO Inc. (RGNX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system.
Price Performance
| 1 month | -27.91% |
| 3 months | +2.31% |
| Year-to-date | -44.58% |
| 1 year | -11.63% |
| 3 years | -55.19% |
| 5 years | -82.28% |
52-Week Range
| 52-week High | $16.19 |
| 52-week Low | $5.46 |
| Avg Volume (90d) | 1.9M |
Technical Indicators
| SMA 50 | $10.33 |
| SMA 200 | $10.20 |
| Beta | 1.13 |
| 30-day Volatility (annualised) | 106.3% |
| Price vs SMA 50 | -22.7% |
| Price vs SMA 200 | -21.8% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $12.77 | |
| 2025-11 | $13.39 | +4.9% |
| 2025-12 | $14.40 | +7.5% |
| 2026-01 | $11.16 | -22.5% |
| 2026-02 | $9.04 | -19.0% |
| 2026-03 | $8.38 | -7.3% |
| 2026-04 | $8.97 | +7.0% |
| 2026-05 | $7.01 | -21.9% |
| 2026-06 | $11.98 | +70.9% |
| 2026-07 | $9.69 | -19.1% |
| 2026-08 | $9.50 | -2.0% |
| 2026-09 | $7.98 | -16.0% |
Price
| Price | $7.98 |
| Market Cap | $413M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 5.87 |
| EV / EBITDA | -3.56 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.96 |
| Current Ratio | 2.86 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -2.57 |